The present invention relates to a cholesterol-synthesis intermediate as pharmaceutically active agent and/or pharmaceutical composition comprising the cholesterol-synthesis intermediate optionally together with one or two further pharmaceutically active agent(s) for use in the prophylaxis and/or treatment of demyelinating disorders/diseases, in particular multiple sclerosis.

The present invention relates to a cholesterol-synthesis intermediate as pharmaceutically active agent and/or pharmaceutical composition comprising the cholesterol-synthesis intermediate optionally together with one or two further pharmaceutically active agent(s) for use in the prophylaxis and/or treatment of demyelinating disorders/diseases, in particular multiple sclerosis.

Provided are a composition for treating or preventing recurrence of keloid comprising tauroursodeoxycholic acid as an active ingredient, and a method for treating keloid or preventing recurrence of keloid using the composition.

Provided are a composition for treating or preventing recurrence of keloid comprising tauroursodeoxycholic acid as an active ingredient, and a method for treating keloid or preventing recurrence of keloid using the composition.

The present invention relates to a method of preventing or treating a fibrotic condition, comprising administering an effective amount of composition to a subject in need thereof; wherein the composition comprises triterpenes extracted from Antrodia camphorate or Anisomeles indica.

The present invention relates to a method of preventing or treating a fibrotic condition, comprising administering an effective amount of composition to a subject in need thereof; wherein the composition comprises triterpenes extracted from Antrodia camphorate or Anisomeles indica.

Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.

Compositions comprising bile acids or their salts and methods of use thereof for the treatment of residual lesions of vascular anomalies.

The present invention is directed to a composition comprising a cannabinoid and lycopene, kits comprising same, and methods of using same, such as for treating a subject afflicted with inflammation.

The present invention is directed to a composition comprising a cannabinoid and lycopene, kits comprising same, and methods of using same, such as for treating a subject afflicted with inflammation.